Figure 3.
Restricted ZIKV replication in MDMs is not due to inefficient virus entry. (A) MDMs were untreated or treated with IL-13 (20 and 50 ng/mL) for 24 h and then subjected to determine the expression levels of ZIKV-related entry factors, including DC-SIGN, AXL, TIM-1, and MERTK by qRT-PCR. moDCs were included as a control. (B) MDMs were untreated or treated with IL-13 (50 ng/mL) for 24 h prior to infection with ZIKVPR or ZIKVU at an MOI of 0.01. The viral genome copy in the cell lysates was determined by qRT-PCR at 24hpi and 48hpi. (C) Viral entry capability in MDMs and moDCs were determined by qRT-PCR and normalized with GAPDH. Data represented mean and standard deviations from 3 donors. Statistical analyses in all panels were performed with one way-ANOVA and the differences were considered significant when p < 0.05. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.